An acute clinical trial evaluating the cardiovascular effects of an herbal ephedra-caffeine weight loss product in healthy overweight adults

International Journal of Obesity

Volumn 26, Issue 10, 2002, Pages 1363-1366

  Kalman, D ^a   Incledon, T ^a   Gaunaurd, I ^a   Schwartz, H ^a   Krieger, D ^a  

^a MIAMI RESEARCH ASSOCIATES   (United States)

Author keywords

Caffeine; Cardiovascular; Ephedrine; Sympathomimetic; Weight loss

Indexed keywords

CAFFEINE; EPHEDRA EXTRACT; HERBACEOUS AGENT; UNCLASSIFIED DRUG; XENADRINE;

ADULT; ARTICLE; BEHAVIOR MODIFICATION; BODY MASS; CARDIOVASCULAR EFFECT; CARDIOVASCULAR FUNCTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET SUPPLEMENTATION; DRUG EFFECT; ELECTROCARDIOGRAPHY; FEMALE; HEART RATE; HUMAN; MALE; OBESITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; WEIGHT REDUCTION;

ADULT; ANTI-OBESITY AGENTS; BLOOD PRESSURE; BODY MASS INDEX; CAFFEINE; CARDIOVASCULAR DISEASES; DOUBLE-BLIND METHOD; ECHOCARDIOGRAPHY, DOPPLER; ELECTROCARDIOGRAPHY; EPHEDRA; FEMALE; HEART RATE; HUMANS; MALE; MIDDLE AGED; OBESITY; PHYTOTHERAPY; TREATMENT OUTCOME;

EPHEDRA;

EID: 0036800631     PISSN: 03070565     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.ijo.0802061     Document Type: Article

References (17)

1. Haller CA, Benowitz NL. Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedrine alkaloids. New Engl J Med 2000; 242: 1833-1838.
2. Schaefer DC, Cheskin LJ. Update on obesity treatment. Gastroenterologist 1998; 6: 136-145.
3. National Institute of Health, National Heart, Lung and Blood Institute. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. US Department of Health and Human Services, Public Health Services: Washington, DC, 1998.
4. Astrup A, Madsen J, Holst JJ, Christensen NJ. The effect of chronic ephedrine treatment on substrate utilization, the sympathoadrenal activity, and energy expenditure during glucose induced thermogenesis in man. Metabolism 1986; 35: 260-265.
5. Jacob LS. Drugs affecting peripheral neurohumoral transmission: Sympathomimetic agents. In: Pharmacology, 4th Edn. Williams & Wilkins: 1996, Baltimore, MD, p 28.
6. Greenway FL. The safety and efficacy of pharmaceutical and herbal caffeine and ephedrine use as a weight loss agent. Obes Rev 2001; 2: 199-211.
7. Dulloo AG, Miller DS. The thermogenic properties of ephedrine/methylxanthine mixtures: Human studies. Int J Obes 1986; 10: 467-481.
8. Boozer CN, Nasser JA, Heymsfield SB, Wang V, Chen G, Solomon JL. An herbal supplement containing Ma Huang-Guarana for weight loss: A randomized, double blind trial. Int J Obes Relat Metab Disord 2001; 25: 316-324.
9. Kalman DS, Colker CM, Shi Q, Swain MA. Effects of a weight loss aid in healthy overweight adults: A double blind clinical trial. Curr Ther Res 2000; 61: 199-207.
10. Daly PA, Krieger DR, Dulloo AG, Young JB, Landsberg L. Ephedrine, caffeine and aspirin: Safety and efficacy for treatment of human obesity. Int J Obes Relat Metab Disord 1993; 17: s73-s78.
11. Astrup A, Tourbo S. Thermogenic, metabolic and cardiovascular responses to ephedrine and caffeine in man. Int J Obes Relat Metab Disord 1993; 17: s41-43.
12. Waluga M, Janusz M, Karpal E, Hartleb M, Nowak A. Cardiovascular effects of ephedrine, caffeine and yohimbine measured by thoracic electrical bioimpedance in obese women. Clin Physiol 1998; 18: 69-76.
13. Penzak SR, Jann MW, Cold JA, Hon YY, Desai HD, Gurley BJ. Seville orange juice: Synephrine content and cardiovascular effects in normotensive adults. J Clin Pharmac 2001; 41: 1059-1063.
14. Pedersen KJ, Kuntz DH, Garbe GJ. Acute myocardial ischemia associated with ingestion of bupropion and pseudoephedrine in a 21-year old man. Can J Cardiol 2001; 17: 599-601.
15. Palinkas A, Picano E, Rodriguez O, Diordjevic-Dikic A, Landi P, Varga A, Ghelarducci B. Safety of ergot stress echocardiography for non-invasive detection of coronary vasospasm. Coron Artery Dis 2001; 12: 649-654.
16. Tun A, Khan IA. Myocardial infarction with normal coronary arteries: The pathologic and clinical perspectives. Angiology 2001; 52: 299-304.
17. Bray GA. Pharmacological treatment of obesity. In: Bray GA, Bouchard C, James WPT (eds). Handbook of Obesity. Marcel Dekker: New York, 1998, pp 876-953.